Stephen From - Jun 4, 2021 Form 4 Insider Report for EYEGATE PHARMACEUTICALS INC (KPRX)

Role: Executive Chairman, Director
Signature: /s/ Sarah Romano, Attorney-in-Fact*
Stock symbol: KPRX
Transactions as of: Jun 4, 2021
Transactions value $: -$3,679
Form type: 4
Date filed: 6/7/2021, 05:02 PM
Next filing: Jul 6, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPRX	Common Stock	Tax liability	-$3.68K	-878	-1.24%	$4.19^*	70.2K	Jun 4, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sale of shares to cover taxes due on restricted stock that vested on 06/01/2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 to $4.39, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Content

Sale of shares to cover taxes due on restricted stock that vested on 06/01/2021.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.19 to $4.39, inclusive. The reporting person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.